Dianthus Therapeutics, Inc. (DNTH) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Dianthus Therapeutics, Inc. (DNTH) closed at USD 74.76 on 2026-10-14, a change of +122 % over the past year, with a market capitalization of USD 4.07B.

Dianthus Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Dianthus Therapeutics, Inc. key figures

Previous close

USD 74.76 (2026-10-14)

1-year change

+122 %

Market cap

USD 4.07B

Enterprise value

USD 3.28B

P/E ratio (trailing)

-17.58

P/E ratio (forward)

-16.16

EPS (trailing)

-4.24

EPS (forward)

-4.61

PEG ratio

n/a

Price to book

3.48

Revenue growth

294.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.65

Employees

92

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Dianthus Therapeutics, Inc. and compare it with other stocks.